Celecoxib for the treatment of musculoskeletal arthritis

References

• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–2038.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising? Results from olmsted county, minnesota, 1955–2007. Arthritis Rheum. 2010;62:1576–1582.
   PubMed Web of Science ®Google Scholar
• Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63:633–639.
   PubMed Web of Science ®Google Scholar
• Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1316–1322.
   PubMed Web of Science ®Google Scholar
• Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1323–1330.
   PubMed Web of Science ®Google Scholar
• Johnson VL, Hunter DJ. The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol. 2014;28:5–15.
   PubMed Web of Science ®Google Scholar
• Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage. 2013;21:1145–1153.
   PubMed Web of Science ®Google Scholar
• Clinical trials database: U.S. National institutes of health; 2019 cited 2019 Mar 15. Available from: www.clinicaltrials.gov
   Google Scholar
• Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376:173–179.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3:133–141.
   PubMed Web of Science ®Google Scholar
• FDA. Celebrex summary review; 2006 cited 2019 Mar 22. Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM162532.pdf
   Google Scholar
• Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921–1928.
   PubMed Web of Science ®Google Scholar
• Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000;38:225–242.
   PubMed Web of Science ®Google Scholar
• Pfizer - Celebrex Dosage and Administration. 2018 cited 2019 Mar 15. Available from: https://www.pfizermedicalinformation.com/en-us/celebrex/dosage-admin
   Google Scholar
• Antman EM. Evaluating the cardiovascular safety of nonsteroidal anti-inflammatory drugs. Circulation. 2017;135:2062–2072.
   PubMed Web of Science ®Google Scholar
• MacDonald TM, Hawkey CJ, Ford I, et al. Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). Eur Heart J. 2017;38:1843–1850.
   PubMed Web of Science ®Google Scholar
• Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40:1347–1365.
   PubMed Web of Science ®Google Scholar
• Kurumbail RG, Kiefer JR, Marnett LJ. Cyclooxygenase enzymes: catalysis and inhibition. Curr Opin Struct Biol. 2001;11:752–760.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Gurbel PA. Cardiovascular safety of NSAIDs: additional insights after PRECISION and point of view. Clin Cardiol. 2017;40:1352–1356.
   PubMed Web of Science ®Google Scholar
• Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA. 1994;91:12013–12017.
   PubMed Web of Science ®Google Scholar
• Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol. 2015;15:511–523.
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology. 2018;154:500–514.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Cannon PJ. Physiology. COX-2 inhibitors and cardiovascular risk. Science. 2012;336:1386–1387.
   PubMed Web of Science ®Google Scholar
• Yu Y, Ricciotti E, Scalia R, et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med. 2012;4:132ra54.
   PubMed Web of Science ®Google Scholar
• Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest. 2001;108:7–13.
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Di Francesco L, et al. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007;82:85–94.
   PubMed Web of Science ®Google Scholar
• James MJ, Cleland LG. Cyclooxygenase-2 inhibitors: what went wrong? Curr Opin Clin Nutr Metab Care. 2006;9:89–94.
   PubMed Web of Science ®Google Scholar
• Walker C. Are all oral COX-2 selective inhibitors the same? A consideration of celecoxib, etoricoxib, and diclofenac. Int J Rheumatol. 2018;2018:1302835.
   PubMed Web of Science ®Google Scholar
• Antoniou K, Malamas M, Drosos AA. Clinical pharmacology of celecoxib, a COX-2 selective inhibitor. Expert Opin Pharmacother. 2007;8:1719–1732.
   PubMed Web of Science ®Google Scholar
• Sandberg M, Yasar U, Stromberg P, et al. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol. 2002;54:423–429.
   PubMed Web of Science ®Google Scholar
• Paulson SK, Kaprak TA, Gresk CJ, et al. Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. Biopharm Drug Dispos. 1999;20:293–299.
   PubMed Web of Science ®Google Scholar
• Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41:1591–1602.
   PubMed Web of Science ®Google Scholar
• Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999;354:2106–2111.
   PubMed Web of Science ®Google Scholar
• Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc. 1999;74:1095–1105.
   PubMed Web of Science ®Google Scholar
• Zhao SZ, McMillen JI, Markenson JA, et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy. 1999;19:1269–1278.
   PubMed Web of Science ®Google Scholar
• Zhao SZ, Fiechtner JI, Tindall EA, et al. Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib. Arthritis Care Res. 2000;13:112–121.
   PubMed Web of Science ®Google Scholar
• Choi IA, Baek HJ, Cho CS, et al. Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. BMC Musculoskelet Disord. 2014;15:375.
   PubMed Web of Science ®Google Scholar
• Gordo AC, Walker C, Armada B, et al. Efficacy of celecoxib versus ibuprofen for the treatment of patients with osteoarthritis of the knee: A randomized double-blind, non-inferiority trial. J Int Med Res. 2017;45:59–74.
   PubMed Web of Science ®Google Scholar
• Tindall EA, Sharp JT, Burr A, et al. A 12-month, multicenter, prospective, open-label trial of radiographic analysis of disease progression in osteoarthritis of the knee or hip in patients receiving celecoxib. Clin Ther. 2002;24:2051–2063.
   PubMed Web of Science ®Google Scholar
• Essex MN, Bhadra P, Sands GH. Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial. J Int Med Res. 2012;40:1357–1370.
   PubMed Web of Science ®Google Scholar
• Essex MN, Behar R, O’Connell MA, et al. Efficacy and tolerability of celecoxib and naproxen versus placebo in Hispanic patients with knee osteoarthritis. Int J Gen Med. 2014;7:227–235.
   PubMedGoogle Scholar
• Essex MN, O’Connell MA, Behar R, et al. Efficacy and safety of nonsteroidal anti-inflammatory drugs in Asian patients with knee osteoarthritis: summary of a randomized, placebo-controlled study. Int J Rheum Dis. 2016;19:262–270.
   PubMed Web of Science ®Google Scholar
• Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390:e21–e33.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med. 2000;343:1520–1528. 2 p following 8.
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102.
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081–1091.
   PubMed Web of Science ®Google Scholar
• Cotter J, Wooltorton E. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). CMAJ. 2005;172:1299.
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–1080.
   PubMed Web of Science ®Google Scholar
• Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005;165:978–984.
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8:e1001098.
   PubMed Web of Science ®Google Scholar
• Back M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J. 2012;33:1928–1933.
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
   PubMed Web of Science ®Google Scholar
• White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007;99:91–98.
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol. 2006;98:266–274.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330:1366.
   PubMed Web of Science ®Google Scholar
• Collaborative overview of randomised trials of antiplatelet therapy–I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet trialists’ collaboration. BMJ. 1994Jan 8;308(6921):81–106.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375:2519–2529.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Husni ME, Libby PA, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial. Am J Med. 2017;130:1415–22 e4.
   PubMed Web of Science ®Google Scholar
• Bhala N, Emberson J, Merhi A, et al.; Coxib, traditional NTC. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–779.
   PubMed Web of Science ®Google Scholar
• FitzGerald GA. Imprecision: limitations to interpretation of a large randomized clinical trial. Circulation. 2017;135:113–115.
   PubMed Web of Science ®Google Scholar
• Schror K, Nitschmann S. Cardiovascular safety of celecoxib: prospective randomized evaluation of celecoxib integrated safety versus ibuprofen or naproxen (PRECISION). Internist (Berl). 2017;58:863–865.
   PubMed Web of Science ®Google Scholar
• Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909.
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA. 2000;284:1247–1255.
   PubMed Web of Science ®Google Scholar
• Loewen PS. Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects. CJEM. 2002;4:268–275.
   PubMedGoogle Scholar
• Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ. 2002;324:1287–1288.
   PubMed Web of Science ®Google Scholar
• Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347:2104–2110.
   PubMed Web of Science ®Google Scholar
• Lai KC, Chu KM, Hui WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005;118:1271–1278.
   PubMed Web of Science ®Google Scholar
• Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369:1621–1626.
   PubMed Web of Science ®Google Scholar
• Chan FKL, Ching JYL, Tse YK, et al. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet. 2017;389:2375–2382.
   PubMed Web of Science ®Google Scholar
• Rahme E, Barkun AN, Toubouti Y, et al. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib? Arthritis Rheum. 2007;57:748–755.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol. 2001;96:1019–1027.
   PubMed Web of Science ®Google Scholar
• Laine L, Curtis SP, Langman M, et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008;135:1517–1525.
   PubMed Web of Science ®Google Scholar
• Yeomans ND, Graham DY, Husni ME, et al. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther. 2018;47:1453–1463.
   PubMed Web of Science ®Google Scholar
• Tsujimoto S, Mokuda S, Matoba K, et al. The prevalence of endoscopic gastric mucosal damage in patients with rheumatoid arthritis. PLoS One. 2018;13:e0200023.
   PubMed Web of Science ®Google Scholar
• Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.
   PubMed Web of Science ®Google Scholar
• Gardiner SJ, Doogue MP, Zhang M, et al. Quantification of infant exposure to celecoxib through breast milk. Br J Clin Pharmacol. 2006;61:101–104.
   PubMed Web of Science ®Google Scholar
• Hale TW, McDonald R, Boger J. Transfer of celecoxib into human milk. J Hum Lact. 2004;20:397–403.
   PubMed Web of Science ®Google Scholar
• Knoppert DC, Stempak D, Baruchel S, et al. Celecoxib in human milk: a case report. Pharmacotherapy. 2003;23:97–100.
   PubMed Web of Science ®Google Scholar
• Hootman JM, Helmick CG, Barbour KE, et al. Updated projected prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation among US adults, 2015–2040. Arthritis Rheumatol. 2016;68:1582–1587.
   PubMed Web of Science ®Google Scholar
• Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375:2293–2297.
   PubMed Web of Science ®Google Scholar